Palvella Therapeutics, Inc. (PVLA) — SEC Filings
Palvella Therapeutics, Inc. (PVLA) — 44 SEC filings. Latest: 8-K (May 7, 2026). Includes 21 8-K, 6 10-Q, 6 SC 13G/A.
View Palvella Therapeutics, Inc. on SEC EDGAR
Overview
Palvella Therapeutics, Inc. (PVLA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 31, 2026: Palvella Therapeutics, Inc. (PVLA) completed a merger on December 13, 2024, with Legacy Palvella, shifting its focus to developing novel therapies for rare skin diseases and vascular malformations. The company reported positive topline results in February 2026 from its Phase 3 SELVA study for QTORIN
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Palvella Therapeutics, Inc. is neutral.
Filing Type Overview
Palvella Therapeutics, Inc. (PVLA) has filed 21 8-K, 1 ARS, 3 10-K, 6 10-Q, 2 DEF 14A, 1 S-1/A, 1 S-1, 6 SC 13G/A, 2 SC 13G, 1 10-K/A with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of PVLA's 31 recent filings, 3 were flagged as high-risk, 14 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | N/A |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Industry Context
Palvella Therapeutics operates in the specialized biotechnology sector focused on rare diseases and vascular malformations. This niche market often presents opportunities for targeted therapies due to unmet medical needs, but also requires significant investment in clinical development and regulatory pathways. The competitive landscape includes other biopharmaceutical companies developing novel treatments for similar conditions.
Top Tags
corporate-action (7) · financials (6) · corporate-governance (5) · Biotechnology (4) · name-change (4) · 10-Q (4) · Rare Diseases (3) · financial-reporting (3) · pharmaceuticals (3) · biotech (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of common equity held by non-affiliates | $196.7 million | As of June 30, 2025, indicating company size |
| Shares of Common Stock outstanding | 14,313,659 | As of March 25, 2026, indicating current share count |
| mLM Investigator Global Assessment (mLM-IGA) improvement | +2.13 | Primary endpoint achievement in Phase 3 SELVA study for QTORIN rapamycin (p<0.001) |
| Estimated diagnosed patients in the U.S. with microcystic LMs | 30,000+ | Represents the potential market size for QTORIN rapamycin |
| Participants enrolled in SELVA Phase 3 trial | 51 | Exceeded target enrollment for the microcystic LM study |
| Minimum age for QTORIN rapamycin treatment in SELVA study | 3 years | Indicates the broad patient population targeted |
| Net Loss | $29.001M | Increased from $13.483 million for the nine months ended September 30, 2024, representing a 115% increase. |
| Research and Development Expenses | $15.720M | Increased from $5.608 million for the nine months ended September 30, 2024, indicating a 180% increase. |
| General and Administrative Expenses | $11.578M | Increased from $4.121 million for the nine months ended September 30, 2024, indicating a 181% increase. |
| Cash and Cash Equivalents | $63.567M | Decreased from $83.602 million at December 31, 2024, representing a 23.96% decrease. |
| Total Stockholders' Equity | $38.682M | Decreased from $62.607 million at December 31, 2024, representing a 38.21% decrease. |
| Net Loss Per Share (3 months) | $1.03 | For the three months ended September 30, 2025, compared to $3.94 in 2024. |
| Net Loss Per Share (9 months) | $2.63 | For the nine months ended September 30, 2025, compared to $7.95 in 2024. |
| Common Shares Outstanding | 11,088,329 | As of September 30, 2025, up from 11,012,105 at December 31, 2024. |
| Net Cash Used in Operating Activities | $20.080M | For the nine months ended September 30, 2025, significantly higher than $5.447 million in 2024. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Palvella Therapeutics, Inc. (PVLA)?
Palvella Therapeutics, Inc. has 44 recent SEC filings from Feb 2024 to May 2026, including 21 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PVLA filings?
Across 44 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 40 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Palvella Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Palvella Therapeutics, Inc. (PVLA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Palvella Therapeutics, Inc.?
Key financial highlights from Palvella Therapeutics, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PVLA?
The investment thesis for PVLA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Palvella Therapeutics, Inc.?
Executive information for Palvella Therapeutics, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Palvella Therapeutics, Inc. stock?
Of PVLA's 31 assessed filings, 3 were flagged high-risk, 14 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Palvella Therapeutics, Inc.?
Forward guidance and predictions for Palvella Therapeutics, Inc. are extracted from SEC filings as they are enriched.